Bi-specific antibodies are an attractive modality to modulate multiple targets in a disease indication.  Each antigen may exhibit similar or different kinetic values like half-life, internalization rates, and expression rates.  Target coverage for each antigen may also differ or be similar.   

Understanding your drug targets is critical to building an appropriate drug that specifically binds to and elicits the magnitude and duration of response needed for a particular indication.  Here we used a tiered model-based approach to first determine feasibility of a bi-specific antibody to appropriately cover multiple antigen pairs.  Once feasibility was assessed, further modeling was performed to determine ideal affinity ranges for each target in bi-specific format at the site of action.  Sensitivity analysis was performed to understand each parameter and its impact on predicted target coverage.  This approach guided teams for informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs.  

Featured Speaker

Jennifer Fretland, PhD

Head of DMPK US
Sanofi

Jennifer received her PhD in Biochemistry and Molecular Biology from the University of Louisville and did her post-doctoral fellowship at the University of Washington (Seattle) in the Department of Pharmacology.  Jennifer has held multiple rising positions in Drug Metabolism and Pharmacokinetic Departments in the Pharmaceutical Industry supporting both biotherapeutics and synthetic molecules. She has supported regulatory submissions for multiple modalities and is now leading a DMPK department that works with multispecific biotherapeutics as well as other modalities.  

Date:  Tuesday, February 4, 2020
Time:  2pm ET / 11am PT
Duration:  1 Hour

Register now for this webinar